1 / 11

Materials: Protocol unavailable Results unavailable – grant not funded

Case Study 13 Designing a simple sequential trial on frequentist principles: a two-stage design with proper a for assessing hyperthermia toxicities in cancer radiotherapy Principal Investigator: Richard Steeves, MD, University of Wisconsin. Materials: Protocol unavailable

jlorrine
Download Presentation

Materials: Protocol unavailable Results unavailable – grant not funded

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Case Study 13Designing a simple sequential trial on frequentist principles: a two-stage design with proper a for assessing hyperthermia toxicities in cancer radiotherapyPrincipal Investigator:Richard Steeves, MD, University of Wisconsin

  2. Materials: Protocol unavailable Results unavailable – grant not funded Information on hyperthermia in cancer treatment available at https://www.cancer.gov/about-cancer/treatment/types/surgery/hyperthermia-fact-sheet Key Words: Power, Size (Type I Error), two-stage designs, single-arm trials, phase II trials. Rick Chappell, Ph.D. Professor, Department of Biostatistics and Medical Informatics University of Wisconsin Medical School Stat 542 – Spring 2018

  3. A single-dose non-escalating toxicity study on concurrent hyperthermia (microwave) and high-dose-rate irradiation for near-surface tumors (UWCCC protocol RO 9471, R. Steeves, M.D., P.I.). We want to show that the toxicity rate isn’t too high using historical controls – so it is a single-arm trial.

  4. To test that the toxicity rate isn’t too high: Let p = Pr(Toxicity). The null hypothesis in this one-arm trial is H0: p = .3 vs. the alternative hypothesis of HA: p = .1 . We hope to reject H0 and conclude HA.

  5. H0: p = .3 vs. HA: p = .1 . What mistakes can we make? Reject H0 when it is true: Type I Error, or False positive Pr(Type I Error) = a = size. Don’t reject H0 when HA is true: Type II Error, or False negative. Pr(Type II Error) = b = 1 - power. (Why don’t I ever write “Accept H0”?)

  6. Suppose we want a simple 1-stage single-arm trial with one-sided a <= .05 and power >= .8 (These are common choices). Use 29 patients and a rejection rule of: Reject H0 if 0 - 4 toxicities; Fail to reject H0 if 5 or more toxicities. Under the binomial formula, a = Pr(Reject H0 | H0) = Pr(0 - 4 toxicities | p = .3) = .038. This isn’t exactly .05, but moving up to 5 toxicities would raise it to .093 which is too high.

  7. Suppose we want a simple 1-stage single-arm trial with one-sided a <= .05 and power >= .8. Under the binomial formula, a = Pr(False positive) = Pr(Reject H0 | H0) = Pr(0 - 4 toxicities | p = .3) = .038. 1 - b = Power = Pr(True positive) = Pr(Reject H0 | HA) = Pr(0 – 4 toxicities | p = .1) = .84.

  8. Now suppose we want a 2-stage single-arm trial with one-sided a = .05 and power = .8, so we can stop early for success or futility. This can be done using 28 patients, with two stages of 14 patients each using the following rules: 0 toxicities in Stage 1: stop and reject H0; 5 or more toxicities in Stage 1: stop and don’t reject H0; 1 - 4 toxicities in Stage 1: continue to Stage 2; 5 or more total toxicities after Stage 2: don’t reject H0; Less than 5 total toxicities after Stage 2: reject H0.

  9. How to Figure Out? Under H0: π = .3 # of events in 2nd cohort of 14 0 1 2 3 4 5 6 7 …. 14 0 1 2 3 4 5 6 . . . 14 # of events in 1st cohort of 14

  10. How to Figure Out? Under H0: π = .3 # of events in 2nd cohort of 14 0 1 2 3 4 5 6 7 …. 14 0 1 2 3 4 5 6 . . . 14 Pr (Reject at Stage 1) = .68% Pr (Reject at Stage 2) Pr (Go to Stage 2, don’t reject) = 4.3% = 53.3% # of events in 1st cohort of 14 Pr (Stop, don’t reject at Stage 1) = 41.7% a = Size = Total False Rejection Rate = 4.3% + .68% = 5.0%

  11. How to Figure Out? Under HA: π = .1 # of events in 2nd cohort of 14 0 1 2 3 4 5 6 7 …. 14 0 1 2 3 4 5 6 . . . 14 Pr (Stop, reject at Stage 1) = 23% Pr (Reject at Stage 2) Pr (Go to Stage 2, don’t reject) = 63% = 13% # of events in 1st cohort of 14 Pr (Stop, don’t reject at Stage 1) = .9% Power to detect (π= .1) = 23% + 63% = 86%

More Related